Atherosclerotic Cardiovascular Disease
Sep 03, 2024
Bayer Phase III NSCLC Trial; D&D Pharmatech Gets FDA Nod for GLP-1R Agonist in Multiple Scletosis; Merck Halts Two KEYTRUDA Trials; Novartis Expands LEQVIO After Phase III Success; Alnylam Reports Strong Phase III Data for Vutrisiran
Bayer Starts Phase III Trial In Non-Small Cell Lung Cancer (NSCLC) Bayer has officially enrolled the first patient in the global Phase III SOHO-02 trial, which will evaluate the efficacy and safety of BAY 2927088 as a first-line treatment for advanced non-small cell lung cancer (NSCLC) with activating HER2 mutat...
Read More...
Jan 29, 2024
Atherosclerotic Cardiovascular Disease (ASCVD) Treatment Approaches: Beyond Statins
Atherosclerotic cardiovascular disease (ASCVD) is a leading cause of morbidity and mortality worldwide, encompassing conditions such as coronary artery disease and stroke. The growing occurrence of ASCVD, fueled by elevated risk factors, cardiovascular disease, and diabetes, is contributing to an expanding market f...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
